ZYUS Life Sciences Corporation
Research ZYUS Life Sciences Corporation (ZYUS) on Bullrun: market cap CAD 39.86M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerZYUS
- ExchangeV
- CountryCanada
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyCAD
- Market capCAD 39.86M
- Financial periodQ1 2026
- RevenueCAD 122.00K
- Net income-CAD 3.06M
- Free cash flow-CAD 1.39M
- Gross margin45.1%
Valuation Snapshot
latest market cap is CAD 39.86M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 405.00K | -CAD 21.73M | -CAD 9.24M | 12.3% | n/a | CAD 233.00K | CAD 15.94M | -CAD 21.12M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-18 | CAD 39.86M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CAD.
About ZYUS Life Sciences Corporation
ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates for medical and adult recreational. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2a clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. It operates in Canada, the United States, Australia, and the European Union.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ZYUS Life Sciences Corporation's market cap?
ZYUS Life Sciences Corporation's market capitalization is CAD 39.86M.
What does ZYUS Life Sciences Corporation do?
ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates for medical and adult recreational. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2a clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. It operates in Canada, the United States, Australia, and the European Union. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.